The Latest
COUR Pharmaceuticals Secures $105 Million in Series A Financing Co-Led by Lumira Ventures and Alpha Wave Ventures
Skip to primary navigation
Skip to main content
Skip to footer
COUR Pharmaceuticals
Our Company
Leadership
Advisors
Partners
Contact
Our Technology
Pipeline
Autoimmune Diseases
Rare Diseases
Gene Therapy
Our Clinical Trials
CNP-104 Primary Biliary Cholangitis
CNP-106 Myasthenia Gravis
Publications & Media
Press Releases
Publications
Careers
Presentation: Phase 2 Celiac Disease Data from UEG Week 2019
View Presentation Here